Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis

• DOI: 10.1016/j.ijcard.2015.01.069
• Publication Date: 2015-01-27T20:06:16Z
• Authors: Anne Tournadre; Zuzana Tatar; Bruno Pereira; Maxime Chevreau; Laure Gossec; Philippe Gaudin; Martin Soubrier; Maxime Dougados
• Keywords: Adult; Male; Cardiology; 610; Risk Assessment; Arthritis, Rheumatoid; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system; Risk Factors; 616; Humans; Rheumatoid arthritis; Amino Acids; Aged; Dyslipidemias; Risk Management; Statins; American Heart Association; Middle Aged; Cardiovascular risk; United States; [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system; 3. Good health; Dyslipidemia; Cardiovascular Diseases; Practice Guidelines as Topic; Female; France; Cardiology and Cardiovascular Medicine

Patients with rheumatoid arthritis (RA) have greater rates of cardiovascular mortality and RA is an independent cardiovascular risk factor. For the management of cholesterol, the American College of Cardiology/American Heart Association (ACC/AHA) developed new guidelines for the general population. None of the European or American guidelines are specific to RA. The European League Against Rheumatism (EULAR) recommends applying a coefficient to cardiovascular risk equations based on the characteristics of RA. Our objective was to compare the three different sets of guidelines for the eligibility of statin therapy in RA-specific population with very high risk of cardiovascular disease.We calculated the proportion of patients eligible for statins according to the guidelines of the European Society of Cardiology (ESC), the Adult Treatment Panel III (ATP-III) and the ACC/AHA in a French cohort of statin-naïve RA patients at least 40 years age. Of the 547 women and 130 men analyzed, statins would be recommended for 9.1% of the women and 26.4% of the men, 15.6% of the women and 53.1% of the men, 38.8% of the women and 78.5% of the men, according to the ESC, ATP-III and ACC/AHA guidelines respectively.In RA patients, as has been observed in the general population, discordance in risk assessment and cholesterol treatment was observed between the three sets of guidelines. The use of the new ACC/AHA guidelines would expand the eligibility for statins and may be applied to RA population a condition at very high risk of cardiovascular disease.